Global Non-Hodgkin Lymphoma Therapeutics Market 2014-2018

Global Non-Hodgkin Lymphoma Therapeutics Market 2014-2018

Category : Healthcare
Published On : June  2014
Pages : 91



TOLL FREE
+1-971-202-1575
------------ Or -------------
help@researchbeam.com

Non-Hodgkin lymphoma (NHL) is a condition of the human body leading to the production of abnormal lymphocytes. In normal circumstances, the lymphocytes grow and die. However, in NHL they do not die; instead they grow and further divide. NHL can begin either in the T-cells or B-cells, though mostly it begins in the B-cells. The location of NHL is generally in the lymph nodes, but it can also spread to the body’s lymphatic system. It has many symptoms, of which swelling in the lymph nodes, abdominal pain, chest pain, cough, fever, fatigue, and night sweats are the most prominent. The causes of this disease are still unknown to scientists. NHL is linked with risk factors such as the overuse of immunosuppressant drugs, viruses such as HIV or Epstein-Barr, and bacteria such as Helicobacter pylori. NHL can be diagnosed by urine tests, physical examination for the enlargement of the lymph nodes, imaging tests (scans) such as magnetic resonance imaging (MRI) or computerized tomography (CT), and biopsy tests.

TechNavio’s analysts forecast the Global Non-Hodgkin Lymphoma Therapeutics market will grow at a CAGR of 7.03 percent over the period 2014-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Non-Hodgkin Lymphoma Therapeutics market for the period 2014-2018. The Global Non-Hodgkin Lymphoma Therapeutics market will observe a high growth in the forecast period. It is due to the availability of the biosimilars at a reduced price across the NHL market. This will be mainly due to the growth of the drug Rituxan in the global market. Apart from that, the market will also grow as a result of the improved diagnostic techniques to detect NHL. Besides, the increase in public awareness about NHL and robust drug pipeline for the treatment of NHL are the major influencers in the growth of the Global Non-Hodgkin Lymphoma Therapeutics market.

TechNavio’s report, the Global Non-Hodgkin Lymphoma Therapeutics Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Non-Hodgkin Lymphoma Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • EMEA
  • APAC

Key Vendors

  • Bristol Myers Squibb Co.
  • Celgene Corp.
  • Eli Lilly and Co.
  • F. Hoffman La-Roche Ltd.
  • GlaxoSmithKline plc

Other Prominent Vendors

  • Accredo Health Group Inc.
  • Baxter International Inc.
  • Bayer AG
  • Cephalon Inc.
  • Eisai Pharmaceuticals Inc.
  • Genelabs Technologies Inc.
  • Hospira Inc.
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Millenium Pharmaceuticals Inc.
  • Pacira Pharmaceuticals Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Teva Pharmaceuticals Inc.

Key Market Driver

  • Availability of Biosimilars at a Reduced Price.
  • For a full, detailed list, view our report.

Key Market Challenge

  • High Cost of NHL Drugs.
  • For a full, detailed list, view our report.

Key Market Trend

  • Dominance of NHL Market by Biologics.
  • For a full, detailed list, view our report.

Key Questions Answered in this Report

  • What will the market size be in 2018 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

01. Executive Summary



02. List of Abbreviations



03. Scope of the Report

03.1 Market Overview

03.2 Product Offerings

03.2.1 Product Profiles



04. Market Research Methodology

04.1 Market Research Process

04.2 Research Methodology



05. Introduction



06. Market Landscape

06.1 Market Overview

06.2 Market Size and Forecast

06.3 Five Forces Analysis



07. Rate of Incidence and Prevalence



08. Market Segmentation by Type of Therapy

08.1.1 Chemotherapy

08.1.2 Targeted Therapy

09. Pipeline Portfolio



10. Geographical Segmentation



11. Buying Criteria



12. Market Growth Drivers



13. Drivers and their Impact



14. Market Challenges



15. Impact of Drivers and Challenges



16. Market Trends



17. Trends and their Impact



18. Vendor Landscape

18.1 Competitive Scenario

18.1.1 Key News

18.1.2 Mergers and Acquisitions

18.2 Market Share Analysis 2013

18.3 Other Prominent Vendors



19. Key Vendor Analysis

19.1 Bristol-Myers Squibb Co.

19.1.1 Key Facts

19.1.2 Business Overview

19.1.3 Product Segmentation

19.1.4 Sales by Geography

19.1.5 Business Strategy

19.1.6 Key Information

19.1.7 SWOT Analysis

19.1.8 Strengths

19.1.9 Weaknesses

19.1.10 Opportunities

19.1.11 Threats

19.2 Celgene Corp.

19.2.1 Key Facts

19.2.2 Business Overview

19.2.3 Business Strategy

19.2.4 Business Segmentation by Revenue 2011-2013

19.2.5 Sales by Geography

19.2.6 Key Developments

19.2.7 SWOT Analysis

19.2.8 Strengths

19.2.9 Weaknesses

19.2.10 Opportunities

19.2.11 Threats

19.3 Eli Lilly and Co.

19.3.1 Key Facts

19.3.2 Business Overview

19.3.3 Business Segmentation by Revenue 2013

19.3.4 Business Segmentation by Revenue 2012 and 2013

19.3.5 Sales by Geography

19.3.6 Business Strategy

19.3.7 Key Developments

19.3.8 SWOT Analysis

19.3.9 Strengths

19.3.10 Weaknesses

19.3.11 Opportunities

19.3.12 Threats

19.4 F. Hoffmann La Roche Ltd.

19.4.1 Key Facts

19.4.2 Business Overview

19.4.3 Business Segmentation

19.4.4 Business Segmentation by Revenue 2012 and 2013

19.4.5 Sales by Geography

19.4.6 Business Strategy

19.4.7 Key Information

19.4.8 SWOT Analysis

19.4.9 Strengths

19.4.10 Weaknesses

19.4.11 Opportunities

19.4.12 Threats

19.5 GlaxoSmithKline plc

19.5.1 Key Facts

19.5.2 Business Overview

19.5.3 Business Segmentation

19.5.4 Business Segmentation by Revenue 2012 and 2013

19.5.5 Sales by Geography

19.5.6 Pipeline Products

19.5.7 Business Strategy

19.5.8 Key Information

19.5.9 SWOT Analysis

19.5.10 Strengths

19.5.11 Weaknesses

19.5.12 Opportunities

19.5.13 Threats



20. Other Reports in this Series



List of Exhibits:



Exhibit 1: Market Research Methodology

Exhibit 2: Global Non-Hodgkin Lymphoma therapeutics market (in US$ billions)

Exhibit 3: Global Non-Hodgkin Lymphoma Therapeutics Market by Type of Therapy

Exhibit 4: Pipeline Portfolio of Global Non-Hodgkin Lymphoma Therapeutics Market

Exhibit 5: Global NHL Therapeutics Market by Geographical Segmentation 2013

Exhibit 6: Bristol-Myers Squibb Co.: Product Segmentation (Based on Therapeutic Areas)

Exhibit 7: Bristol-Myers Squibb Co.: Sales by Geography 2013

Exhibit 8: Celgene Corp.: Business Segmentation by Revenue 2011-2013 (US$ million)

Exhibit 9: Celgene Corp.: Sales by Geography 2013

Exhibit 10: Eli Lilly and Co.: Business Segmentation by Revenue 2013

Exhibit 11: Eli Lilly and Co.: Business Segmentation by Revenue 2012 and 2013 (US$ million)

Exhibit 12: Eli Lilly and Co.: Sales by Geography 2013

Exhibit 13: Business Segmentation of F. Hoffmann-La Roche Ltd. 2013

Exhibit 14: F. Hoffmann-La Roche Ltd: Business Segmentation by Revenue 2012 and 2013

Exhibit 15: F. Hoffmann-La Roche Ltd: Sales by Geography 2013 (Pharmaceuticals Division)

Exhibit 16: F. Hoffmann-La Roche Ltd: Sales by Geography 2013 (Diagnostics Division)

Exhibit 17: GlaxoSmithKline Plc: Business Segmentation 2013

Exhibit 18: GlaxoSmithKline Plc: Business Segmentation by Revenue 2012 and 2013 (in US$ billion)

Exhibit 19: GlaxoSmithKline Plc: Sales by Geography 2013

Exhibit 20: GlaxoSmithKline plc: Pipeline Products 2013


Enquiry Before Buy
image
Can´t read the image ? refresh here.